Alnylam Pharmaceuticals rStock

Alnylam Pharmaceuticals, Inc. is a leading global biopharmaceutical company at the forefront of developing innovative RNA interference (RNAi) therapeutics. The company pioneered the translation of Nobel Prize-winning science into an entirely new class of innovative medicines. Utilizing its proprietary drug delivery technology platforms, Alnylam is dedicated to the R&D, manufacturing, and commercialization of breakthrough small interfering RNA (siRNA) medicines targeting rare diseases, cardiovascular conditions, metabolic disorders, and central nervous system diseases. As an industry pioneer, it possesses a strong core moat in the commercialization and pipeline expansion of gene-silencing technologies.